Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | BT8009 is a conjugate targeting Nectin-4, demonstrating a dissociation constant (Kd) of 2.5 nmol/L for the hNectin-4 ECD. This compound comprises a Nectin-4-specific bicyclic peptide, a cleavable linker, and MMAE. It is applicable in the study of advanced and metastatic urothelial cancer [1]. |
In vitro | BT8009 exhibits an 'apparent affinity' for the endogenous Nectin-4 expressed on the MDA-MB-468 cell membrane, with a binding concentration of 12.9 nmol/L [1]. |
In vivo | BT8009, administered intravenously at doses of 1, 2, and 3 mg/kg once weekly for five weeks, demonstrated antitumor activity in mouse xenograft models of triple-negative breast cancer and non-small cell lung cancer [1]. The maximum tolerated dose (MTD) of BT8009 was established at 5 mg/kg in rats and 1.5 mg/kg in non-human primates under a five-week dosing regimen [1]. |
Formula | C194H283N45O50S4 |
Cas No. | 2748001-89-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.